Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Biocon Limited - Slow recovery in biosimilars - ICICI Securities

Posted On: 2021-01-24 22:17:21 (Time Zone: Arizona, USA)


Biocon Limited (Biocon) reported lower than estimated Q3FY21 performance in biosimilars and generics segment. Consolidated revenues grew 7.8% to Rs18.5bn (I-Sec: Rs19.5bn), adjusted EBITDA margin was down 430bps to 21.6% (I-Sec: 25.4%) and adjusted PAT declined 16.9% to Rs1.7bn (I-Sec: Rs2.4bn). Lower margin is attributed to higher R&D expenses and employee costs. Delay in new launches and recovery in the environment would suppress margins in the near term but are expected to improve over medium term as the market normalises from impact of COVID-19. Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar. Reiterate ADD with a revised target price of Rs443/share (earlier: Rs490/share).

- Research steady while generics and biosimilars disappoint: Research services grew 12.6% YoY with steady performance across its business segments. Company added a new project from 3DC that will support growth over medium term. Generics declined 2.6% YoY (-6.4% QoQ) to Rs5.6bn due to inventory correction of API products in the channel which were high in the distressed environment. Biosimilars segment grew 11.0% YoY during the quarter supported by steady market share in Ogiviri and Fulphila in the US and sales from the recently launched Semglee in US market. However, growth has been lower than expected as the company faced operational challenges due to lockdowns, delay in acquiring new tenders and reduced footfalls in hospital services and critical care due to the pandemic.

- Higher R&D and staff costs restrict margin: Company reported an improvement of 170bps in gross margin with improving business mix and higher contribution from biosimilar segment. However, staff and R&D expense jumped 23% and 31% respectively on a YoY basis. This sharp jump in costs is related to higher investment towards the biosimilars and generics pipeline and has hit EBITDA margin, which dropped 430bps YoY (-80bps QoQ) to 21.6%. PBT margins for biosimilars and generics segments declined to 14.4% and 9.6% respectively. Delay in recovery and new launches would suppress margins in the near term but are expected to improve over medium term as the market normalises from impact of COVID-19.

- Outlook: We expect revenue CAGR of 19.3% over FY20-FY23E resulting in EBITDA margin expansion of 450bps (with rising contribution from the high-margin biosimilars segment) and earnings CAGR of 34.2% over FY20E-FY23E. This would help generate healthy FCF of ~Rs11bn over FY21E-FY23E and improve return ratios.

- Valuation and risks: We reduce revenue and EBITDA estimates by 2-4% and 9-12% respectively over FY21E-FY23E to account for delay in new product launches and higher expenses towards R&D and personnel. Maintain ADD with a revised SoTP-based target price of Rs443/share (earlier: Rs490/share) Key downside risks: adverse regulation, delay in product launch, and higher competition in products.

Shares of BIOCON LTD. was last trading in BSE at Rs.393.8 as compared to the previous close of Rs. 441.95. The total number of shares traded during the day was 1386180 in over 39448 trades.

The stock hit an intraday high of Rs. 424 and intraday low of 386. The net turnover during the day was Rs. 556857995.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

Nestle India 1QCY21 results - Views by Himanshu Nayyar, Lead Analyst - Institutional Equities, YES SECURITIES

ICICI Prudential Life Insurance - Q4FY21 Result Update - YES Securities

Power: Sector Thematic - Reforms essential for renaissance - HDFC Securities

ACC 1QCY21 Results Review Report - Strong margins! - HDFC Securities

ICICI Prudential Life 4QFY21 Results Review Report - Strong micro; challenging macro - HDFC Securities

ACC Ltd - Q1CY21 Result Update - YES Securities

ICICI Prudential Life Insurance - Business momentum upwards; valuations remain attractive - ICICI Securities

Multiplex - Business disruption again - learnings and better cash position to help - ICICI Securities

ACC - Strong show led by lower costs - ICICI Securities

Brookfield India REIT - Building a strong edifice - ICICI Securities

Q4FY21 Result Preview - Oil & Gas - ICICI Direct

Q1CY21 Result Update - ACC Ltd - ICICI Direct

ACC Q1CY21 Results - Views by YES SECURITIES

Comments on Rupee from industry experts - April 19, 2021

Autos & Logistics 4QFY21 Results Preview - HDFC Securities

ADD on Mindtree - Gaining momentum - HDFC Securities

ICICI Lombard 4QFY21 Result Review - HDFC Securities

Mindtree - Q4FY21 Result Update - YES Securities

ICICI Lombard - Q4FY21 Result Update - YES Securities

HDFC Bank - Q4FY21 Result Update - YES Securities

Mindtree - Subtle downgrade in outlook! - ICICI Securities

SBI Cards and Payment Services - Play on monetisable payments growth - ICICI Securities

ICICI Lombard General Insurance Company - Cyclical recovery can protract; fundamentals remain intact - ICICI Securities

HDFC Bank - Resilience and consistency displayed to its core - ICICI Securities

Home First Finance Company - Tech-led affordable housing play at affordable valuations - ICICI Securities

Q4FY21 Result Update - Wipro Ltd - ICICI Direct

ICICI Direct - Covid Recovery Pulse - E-Way bill generation ends March 2021 on strong note...

Derivatives Strategy - Positional Future - ICICI Direct

Gladiator Stocks - Escorts - ICICI Direct

Q4FY21 Company Update - Tata Metaliks - ICICI Direct

Q4FY21 Result Update - MindTree Ltd - ICICI Direct

Q4FY21 Result Update - HDFC Bank - ICICI Direct

ICICI Direct Derivatives Weekly View (April 16): Sustainability above 14700 may trigger fresh uptrend...

Market Outlook - Technical - By Dharmesh Shah, Head - Technical, ICICIdirect

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on Monsoon outlook

ADD on Wipro - Improving growth visibility - HDFC Securities

Building Materials 4QFY21 Results Preview - Strong demand to support robust margin - HDFC Securities

Consumer Discretionary 4QFY21 Results Preview - Bargains few and far between - HDFC Securities

Consumer Durables 4QFY21 Results Preview - HDFC Securities

Wipro - Q4FY21 Result Update - YES Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 Monthly Trade Balance

Wipro - Q4FY21 Result Update - Lofty multiples leave limited margin of safety - ICICI Securities

FMCG & Alco Bev 4QFY21 Results Preview - HDFC Securities

Maintain BUY on Infosys - Q4FY21 Results Review - Buy the dip - HDFC Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 WPI Data released today

Non-leveraged financials 4QFY21 Results Preview - HDFC Securities

Infosys - A reality check! - ICICI Securities

Infosys - Q4FY21 Result Update - YES Securities

Polymer price tracker - PVC prices continue to rise - April 15, 2021 - ICICI Securities

Bharti Airtel - Restructuring aimed at digital biz, AGR-tax efficiency - ICICI Securities


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020